V-type starch-galloyl-based polyphenol complex stimulates GLP-1 and PYY secretion and improves satiety in mice
Yimei Zheng1, Tonglin Chen1, Ke Li1
1Guangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, 483 Wushan Road, Guangzhou 510642, China.
Polyphenols like gallic acid (GA) and tannic acid (TA) form complexes with high-amylose maize starch (HAMS). These HAMS-TA/GA complexes reduce starch digestion, improve glycemic response, and enhance satiety in mice, suggesting potential for functional foods.
Area of Science:
- Food Science
- Nutritional Science
- Biochemistry
Background:
- Polyphenols are plant compounds with potential health benefits.
- Starch digestibility influences postprandial glycemic response.
- High-amylose maize starch (HAMS) has unique structural properties.
Purpose of the Study:
- To investigate the complex formation between gallic acid (GA) or tannic acid (TA) and HAMS.
- To evaluate the impact of these complexes on in vitro starch digestibility.
- To assess the in vivo effects on glycemic response, hormone levels, and satiety in mice.
Main Methods:
- Complexation of HAMS with GA and TA via noncovalent bonds.
- In vitro digestion assays to determine starch digestion rate (k) and digestible proportion (C∞).
- In vivo studies in mice to measure postprandial glycemic response, GLP-1 and PYY concentrations, and satiety.
Main Results:
- HAMS-TA/GA complexes formed V-type crystalline structures with higher polyphenol loading in HAMS-TA.
- Complexes exhibited reduced in vitro starch digestibility due to increased crystallinity and alpha-amylase inhibition.
- In vivo studies showed lower glycemic response, elevated GLP-1 and PYY, and enhanced satiety with HAMS-TA/GA complexes, particularly HAMS-TA.
Conclusions:
- Starch-galloyl-based polyphenol complexes, especially HAMS-TA, demonstrate potential for functional food development.
- These complexes can modulate starch digestion, glycemic response, and satiety.
- Findings suggest applications in preventing type-2 diabetes and obesity through dietary interventions.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...


